Patents by Inventor Minxue Zheng
Minxue Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10808244Abstract: The present disclosure relates to normalization of biological samples, particularly samples comprising nucleic acids to be sequenced. The normalization protocols described herein may be utilized across multiple samples to cap total stoichiometric input and minimize variations in transcript abundance on a per-sample basis in a multiplexed fashion to dramatically increase the accuracy, capacity and efficiency of nucleic acid sequencing.Type: GrantFiled: March 21, 2019Date of Patent: October 20, 2020Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Thomas Battersby, Adrian Nielsen Fehr, Minxue Zheng
-
Publication number: 20190203202Abstract: The present disclosure relates to normalization of biological samples, particularly samples comprising nucleic acids to be sequenced. The normalization protocols described herein may be utilized across multiple samples to cap total stoichiometric input and minimize variations in transcript abundance on a per-sample basis in a multiplexed fashion to dramatically increase the accuracy, capacity and efficiency of nucleic acid sequencing.Type: ApplicationFiled: March 12, 2019Publication date: July 4, 2019Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Thomas Battersby, Adrian Nielsen Fehr, Minxue Zheng
-
Patent number: 10273473Abstract: The present disclosure relates to normalization of biological samples, particularly samples comprising nucleic acids to be sequenced. The normalization protocols described herein may be utilized across multiple samples to cap total stoichiometric input and minimize variations in transcript abundance on a per-sample basis in a multiplexed fashion to dramatically increase the accuracy, capacity and efficiency of nucleic acid sequencing.Type: GrantFiled: April 4, 2017Date of Patent: April 30, 2019Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Thomas Battersby, Adrian Nielsen Fehr, Minxue Zheng
-
Publication number: 20170247753Abstract: The present disclosure relates to normalization of biological samples, particularly samples comprising nucleic acids to be sequenced. The normalization protocols described herein may be utilized across multiple samples to cap total stoichiometric input and minimize variations in transcript abundance on a per-sample basis in a multiplexed fashion to dramatically increase the accuracy, capacity and efficiency of nucleic acid sequencing.Type: ApplicationFiled: April 4, 2017Publication date: August 31, 2017Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Thomas Battersby, Adrian Nielsen Fehr, Minxue Zheng
-
Patent number: 9695416Abstract: The present disclosure relates to normalization of biological samples, particularly samples comprising nucleic acids to be sequenced. The normalization protocols described herein may be utilized across multiple samples to cap total stoichiometric input and minimize variations in transcript abundance on a per-sample basis in a multiplexed fashion to dramatically increase the accuracy, capacity and efficiency of nucleic acid sequencing.Type: GrantFiled: July 18, 2013Date of Patent: July 4, 2017Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Thomas Battersby, Adrian Nielsen Fehr, Minxue Zheng
-
Publication number: 20150152407Abstract: The present disclosure relates to normalization of biological samples, particularly samples comprising nucleic acids to be sequenced. The normalization protocols described herein may be utilized across multiple samples to cap total stoichiometric input and minimize variations in transcript abundance on a per-sample basis in a multiplexed fashion to dramatically increase the accuracy, capacity and efficiency of nucleic acid sequencing.Type: ApplicationFiled: July 18, 2013Publication date: June 4, 2015Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Thomas Battersby, Adrian Nielsen Fehr, Minxue Zheng
-
Patent number: 8394944Abstract: The present invention provides primers and probes to be used in a method of enhancing hybridization of a probe to a target nucleotide sequence when the target sequence is capable of forming intramolecular secondary structures that interfere with hybridization of the probe to the target sequence. In particular, the invention includes a primer for amplifying a target nucleotide sequence, wherein at least a portion of the target nucleotide sequence can form an intramolecular secondary structure. The primer of the invention includes a primer nucleotide sequence complementary to a portion of the target nucleotide sequence that does not form a secondary structure, and a blocking sequence substantially complementary to at least a portion of the secondary structure-forming region of the amplified target nucleotide sequence, wherein the blocking sequence hybridizes to a portion of the secondary structure-forming region of the amplified target nucleotide sequence and blocks the formation of the secondary structure.Type: GrantFiled: September 15, 2003Date of Patent: March 12, 2013Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Minxue Zheng, John J. Quinn, Brian D. Warner
-
Patent number: 8063196Abstract: The invention provides a set of highly orthogonal six-code universal sequences for use in bDNA singleplex and multiplex nucleic acid hybridization assays. The six-code orthogonal sequences do not cross-hybridize and thus, minimize or eliminate the 3-mer cross-hybridization inherent in the second and third generation bDNA assays. The highly orthogonal universal sequences may be used in singleplex or multiplex bDNA assays quantitatively and qualitatively to determine mRNA levels in a sample; to screen for and genotype targets, such as viruses, that are present in low volumes in a sample; to screen for and genotype SNPs; and to measure changes in the amount of a gene in a sample such as when gene amplifications or deletions occur. The highly orthogonal universal sequences may also be used as universal capture probes to selectively bind assay components in a way that facilitates their further analysis.Type: GrantFiled: February 1, 2005Date of Patent: November 22, 2011Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Minxue Zheng, David Ahle, Brian Warner, Ming Wu, Chu-an Chang
-
Publication number: 20100047800Abstract: The present invention relates to oligonucleotide sequences for amplification primers and detection probes and their use in nucleic acid amplification methods for the specific detection of clinically relevant CYP2C9 polymorphisms, in particular CYP2C9 polymorphisms associated with adverse drug response. The oligonucleotide sequences are also provided assembled as kits that can be used to predict how an individual will respond to drugs or other xenobiotic compounds that are metabolized, at least in part, by CYP2C9.Type: ApplicationFiled: January 22, 2008Publication date: February 25, 2010Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.Inventors: Minxue Zheng, Lailing Ku, Lu-ping Shen, Carrie Wong, Charlene Bush-Donovan
-
Publication number: 20060172284Abstract: The invention provides a set of highly orthogonal six-code universal sequences for use in bDNA singleplex and multiplex nucleic acid hybridization assays. The six-code orthogonal sequences do not cross-hybridize and thus, minimize or eliminate the 3-mer cross-hybridization inherent in the second and third generation bDNA assays. The highly orthogonal universal sequences may be used in singleplex or multiplex bDNA assays quantitatively and qualitatively to determine mRNA levels in a sample; to screen for and genotype targets, such as viruses, that are present in low volumes in a sample; to screen for and genotype SNPs; and to measure changes in the amount of a gene in a sample such as when gene amplifications or deletions occur. The highly orthogonal universal sequences may also be used as universal capture probes to selectively bind assay components in a way that facilitates their further analysis.Type: ApplicationFiled: February 1, 2005Publication date: August 3, 2006Applicant: Bayer HealthCare LLCInventors: Minxue Zheng, David Ahle, Brian Warner, Ming Wu, Chu-an Chang
-
Publication number: 20040132061Abstract: The present invention provides primers and probes to be used in a method of enhancing hybridization of a probe to a target nucleotide sequence when the target sequence is capable of forming intramolecular secondary structures that interfere with hybridization of the probe to the target sequence. In particular, the invention includes a primer for amplifying a target nucleotide sequence, wherein at least a portion of the target nucleotide sequence can form an intramolecular secondary structure. The primer of the invention includes a primer nucleotide sequence complementary to a portion of the target nucleotide sequence that does not form a secondary structure, and a blocking sequence substantially complementary to at least a portion of the secondary structure-forming region of the amplified target nucleotide sequence, wherein the blocking sequence hybridizes to a portion of the secondary structure-forming region of the amplified target nucleotide sequence and blocks the formation of the secondary structure.Type: ApplicationFiled: September 15, 2003Publication date: July 8, 2004Inventors: John J. Quinn, Minxue Zheng, Brian D. Warner